In the fifth episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep (ASX:IMM), explains the complex and heavily regulated process of bringing a new ...

Therefore, for public sites, HREC and an SSA is required for a clinical trial to commence. The most common approval process for clinical trials using unapproved medicines in Australia is via the ...